Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.